Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 161.00p 6,970 09:24:52
Bid Price Offer Price High Price Low Price Open Price
162.50p 164.50p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 1.88 -52.35 9.62 16.3 455.1

Puretech (PRTC) Latest News

More Puretech News
Puretech Takeover Rumours

Puretech (PRTC) Share Charts

1 Year Puretech Chart

1 Year Puretech Chart

1 Month Puretech Chart

1 Month Puretech Chart

Intraday Puretech Chart

Intraday Puretech Chart

Puretech (PRTC) Discussions and Chat

Puretech Forums and Chat

Date Time Title Posts
20/3/201909:43PureTech Health - innovative healthcare311
22/7/201820:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-03-21 16:51:59165.517,87713,037.30O
2019-03-21 16:51:48163.98506829.76O
View all Puretech trades in real-time

Puretech (PRTC) Top Chat Posts

Puretech Daily Update: Puretech Health is listed in the General Financial sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech was 161p.
Puretech Health has a 4 week average price of 157p and a 12 week average price of 157p.
The 1 year high share price is 188.50p while the 1 year low share price is currently 135p.
There are currently 282,679,696 shares in issue and the average daily traded volume is 22,222 shares. The market capitalisation of Puretech Health is £455,114,310.56.
rambutan2: edwardt, i suppose it's in response to this capital raise... Although in the results they said... "Cash and Cash Equivalents: Cash, cash equivalents and marketable securities were $108.0 million as of December 31, 2018, as compared to $53.3 million as of December 31, 2017. The Company expects that current cash, cash equivalents and marketable securities as of December 31, 2018 will be sufficient to fund its operating expenses at least into the second quarter of 2020." So it's not as though they are desperate. Ultimately, of course, the share price will be trial results driven.
lendmeafiver: Vedanta puretech holding was 71.5% I believe, now 63%, they raised usd27, values the company at around usd200m and puretechs holding at circa usd120m fully diluted, about right? Worth about 45p per share alone, please note calculated on an iPhone calculator whilst drinking in a coffee shop so please correct me if I’m wrong! Very encouraging to see some very high profile new investors directly into Vedanta. Anyway I think it’s been a very sold year of progress here, both in the business and a reasonable share price performance, remains hugely undervalued in my opinion, plenty to look forward to in 2019.
lendmeafiver: Very encouraging news, I purchased a few more here this week, well below ipo and share issue prices of course, I expect that at some stage this year there will be sufficient newsflow to really move the share price closer to the brokers targets of circa £3
edwardt: my takes were chances of two more ipos in next 6 months. they are also going to go coy on valuation methodology given sensitivity around pricing on ipo and second rounds - all makes sense to me but will prove hard for analysts to model which could result in vol in share price. i want to sit tight for a decade on this one.
healzo2: I imagine pretty much as you would expect. Great emphasis placed on the award winning, world class calibre of the team, and the pipeline of innovative and potentially lucrative products. Biome / second brain considerations seen as becoming more prominent in public consciousness going forward. Share price seen as heading upwards of 800p in the next 5 years. Possible headwinds listed as the need for further capitalisation and naturally testing failures. One of the better and more convincingly written pamphlets I've read over the years. Seemed based on true conviction rather than usual ramping rubbish.
rambutan2: Getting there: PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Gelesis, Inc. (a subsidiary of PureTech Health) has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study. GLOW was designed to assess the long-term efficacy and safety of lead product candidate Gelesis100 over a six-month period across a broad patient population. Results from this registration-enabling trial are anticipated in Q3 2017. Gelesis has also enrolled its first European patient in the ongoing LIGHT-UP study with its second product candidate, Gelesis200, for weight loss and glycaemic control. LIGHT-UP will enrol individuals across the United States, Canada, and Europe who are overweight or have obesity and also have prediabetes or metformin-treated type 2 diabetes. Dr. Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, said: "We're delighted to have achieved these important milestones and to expand the breadth of the Gelesis platform. As a result of new, preclinical research and the pioneering work of Gelesis in this emerging field of mechanobiology, we are also planning or initiating pilot studies across a number of additional indications including early nonalcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and other gastrointestinal disorders."
lendmeafiver: That was some jump in share price on zero newsflow, back to the IPO price by the end of the week?!
lendmeafiver: Share price has ticked up ever so slightly also, not sure if it's anything to do with that news or Chowrira's continuous buying of stock or a combination of them both.
rambutan2: BOSTON and SAN FRANCISCO, June 28, 2017 - Akili Interactive Labs, Inc. ("Akili") today announced the appointment of former Cubist Pharmaceuticals CEO, Robert J. Perez, as Executive Chairman. Mr. Perez has been a commercial advisor with the company for the past year and will now be joining in the more official leadership role as the company continues its growth. Additionally, the company has added former DreamWorks Interactive CEO, Glenn Entis, and former Chief Game Designer at Google, Noah Falstein, as Executive Advisors. These three biotech and game industry veterans will bring their cross-disciplinary expertise to the Akili team as the company advances its diverse product portfolio and prepares for the potential commercialization of Akili's lead product, Project:EVO(TM) . The Project:EVO(TM) platform is currently being evaluated in a pivotal, registration-enabling trial in patients with paediatric ADHD, which is expected to read out in the second half of 2017.
lendmeafiver: Good Gelesis news, in my view that product covers the current share price on its own!
Puretech share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190322 09:54:25